Market Minds Advisory
Celiac Disease Diagnostics Market

Celiac Disease Diagnostics Market: Serology Screening Meets Genetic And Point-Of-Care Confirmation

Rising physician awareness has pushed serology screening into routine gastrointestinal workups, but the diagnostic pathway still runs through confirmatory biopsy in most health systems, leaving point-of-care and genetic testing adoption well behind their clinical potential.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.9BMarket Size 2025
2036 FORECAST VALUE$2.2BBase Case , 2026 to 2036
CAGR 2026 TO 20368.4 %Bull 9.7% / Bear 7.1%
INCREMENTAL OPPORTUNITY$1.2BNet 10- year value creation
EXPANSION MULTIPLE2.24x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Celiac disease diagnostics is shifting from biopsy-first confirmation toward serology-led screening backed by genetic and point-of-care testing, a change large enough that primary care ordering patterns, not gastroenterologist referral volume alone, now shape most diagnostic pathway decisions across major health systems worldwide today.
Point-of-care testing grows fastest at 13.2%, roughly 1.57 times the overall rate, as clinics and pharmacies increasingly adopt CLIA-waived rapid antibody formats that resolve diagnostic uncertainty within minutes rather than days. North America holds the largest regional share at 28%, reflecting concentrated primary care screening infrastructure and consistent insurance reimbursement for serology panels across major health systems tracked in this review, well ahead of less consistently reimbursed markets elsewhere.
Competitive intensity stays moderate: five manufacturers control under half of revenue, led by Thermo Fisher and DiaSorin through years of accumulated reagent manufacturing and laboratory distribution investment that smaller specialists still struggle to replicate. Rising physician awareness keeps expanding demand across nearly every major primary care network, forcing manufacturers to carry broader accuracy validation data than legacy products required. Indian and Chinese manufacturers are gaining early traction in standard serology specification deals too.
Market Definition
The celiac disease diagnostics market covers serology, genetic, endoscopic biopsy, and point-of-care testing products and services used specifically to diagnose celiac disease. It excludes general gastrointestinal diagnostic panels and celiac disease treatments such as gluten-free dietary products or investigational therapeutics.
Base Year Value
$0.9B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.4% base case. Bull 9.7%. Bear 7.1%.
Fastest Growth Segment
Point-of-Care Rapid Tests: 13.2% CAGR
Fastest Growth Country
India: 10.6% CAGR
Fastest Growth Region
South Asia and Pacific: 10.4% CAGR
Largest Region
North America: 28% of 2025 global value
Market Leaders
Thermo Fisher Scientific, DiaSorin, Bio-Rad Laboratories, Werfen, EUROIMMUN. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Celiac Disease Diagnostics Market Forecast Scenarios

celiac-disease-diagnostics-market-size-forecast-scenario-1787305265994
Between 2020 and 2025 the market grew at roughly 7.6% annually, accelerating steadily as primary care physicians increasingly adopted routine serology screening for patients with nonspecific gastrointestinal symptoms across major health systems worldwide. Physician awareness expanded meaningfully throughout this window, moving celiac testing from a specialist referral decision into a standard primary care ordering pattern at leading clinics.
The base case carries the market to 8.4% annual growth through three commercial mechanisms working together. First, primary care screening keeps expanding as physicians increasingly order serology panels for symptomatic patients. Second, point-of-care adoption keeps rising alongside expanding CLIA-waived rapid test approval activity. Third, India's expanding diagnostic laboratory network keeps converting rising physician awareness into direct testing demand nationwide each year, reinforcing the broader decentralized diagnostics transition already underway. That combined momentum keeps pricing power intact across major reimbursement markets tracked here.
The bull case, 9.7%, assumes accelerated point-of-care approval activity and faster laboratory infrastructure expansion pulls forward testing demand more quickly than currently modeled across major diagnostics markets worldwide, particularly across Asia. The bear case, 7.1%, assumes reimbursement caution and persistent biopsy confirmation requirements keep serology-only diagnosis constrained well beyond the current decade of forecast coverage tracked in this review.

Where Serology Screening Meets Genetic And Point-Of-Care Confirmation

Three forces converge on this market simultaneously. Primary care screening keeps expanding as physicians increasingly order serology panels for symptomatic patients. Point-of-care adoption keeps rising alongside expanding CLIA-waived rapid test approval activity. And India's expanding diagnostic laboratory network keeps converting rising physician awareness into direct testing demand nationwide across its hospital network.
MARKET CONCENTRATIONCR5: 48%Top five diagnostics manufacturers control under half of revenue
AVERAGE TEST COSTUSD 25 to 350 per panelCosts vary sharply between serology screening and genetic confirmation
TOP TESTING COUNTRYUnited States: 24% of test volumeConcentrated primary care screening and reimbursement drive volume here
BIOPSY CONFIRMATION RATE61% of positive serology casesShare of positive screens still referred for endoscopic confirmation
REAGENT COST SHARE38% of COGSAntibody reagent and antigen sourcing dominate production cost structure
RESULT TURNAROUND TIME20 minutes to 10 daysTurnaround varies sharply between point-of-care and laboratory-based testing
Commercially, this market behaves like a specialty diagnostics business layered onto a genuinely underdiagnosed condition funnel that remains incomplete across many regions worldwide. Manufacturers compete on accuracy validation depth and laboratory distribution breadth as much as on price, since clinics increasingly demand published sensitivity data before specifying a test into a standard screening protocol. That validation depth increasingly separates leading manufacturers from smaller competitors across nearly every major diagnostics market tracked here. Buyers increasingly expect published accuracy data before committing to a long-term supply relationship.
Over the next decade expect continued transition beyond biopsy-first confirmation into serology-led and point-of-care pathways. India's laboratory infrastructure will keep anchoring regional volume growth across its expanding diagnostic network. And accuracy validation documentation, more than raw test volume alone, will increasingly determine which manufacturers clinics actually specify into standard celiac disease screening protocols going forward.
"A tTG-IgA test costs less than a routine blood panel, yet most people with celiac disease still go undiagnosed for years because nobody ordered it in the first place."
Director, Gastrointestinal Diagnostics and Autoimmune Testing Practice · MMA Hea

Market Trends

Primary Care Physicians Adopt Routine Serology Screening

Primary care physicians increasingly order tTG-IgA serology panels for patients presenting with nonspecific gastrointestinal symptoms, a practice that has converted celiac disease testing from a specialist referral decision into a routine primary care ordering pattern across major health systems. This shift addresses a genuine diagnosis gap, since patients referred directly to gastroenterology often wait months for an appointment while symptoms persist untreated. Several manufacturers have expanded serology panel marketing toward primary care networks with published sensitivity data, positioning documented screening accuracy as the category's clearest growth driver heading into the next several years of adoption.
Market Impact: Adds 19% share via screening growth

Point-Of-Care Testing Reduces Diagnostic Pathway Delay

Clinics and pharmacies increasingly adopt point-of-care rapid antibody tests that deliver results within twenty minutes, a format that has converted celiac disease screening from a multi-day laboratory referral process into an immediate clinical decision at the point of contact. This shift addresses a genuine access gap, since patients in rural or underserved areas often lack convenient access to central laboratory testing infrastructure. Several manufacturers have launched CLIA-waived point-of-care formats with published accuracy data, positioning documented rapid-result reliability as a durable differentiator across the broader diagnostics industry worldwide. Pharmacy chains increasingly view rapid testing as a routine service line extension.
Market Impact: Anchors 21% of regional testing vol

Market Opportunities and Growth Drivers

Rising Physician Awareness Expands Screening Volume

Medical schools and continuing education programs increasingly cover celiac disease presentation patterns, converting physician awareness into a durable driver of screening volume independent of any single manufacturer's product launch cycle. This creates demand that spans nearly every major primary care network simultaneously, since awareness growth directly increases the population of patients who receive a serology order rather than a symptomatic misdiagnosis. Manufacturers increasingly fund physician education partnerships alongside test marketing, converting what was once a narrow specialist niche into a broader primary care screening category across the wider health system.
Market Impact: Adds 4 to 8 months

India's Diagnostic Lab Network Expansion Anchors Regional Demand

India's continued investment in diagnostic laboratory infrastructure keeps converting rising physician awareness directly into testing demand capable of serving both established urban hospital networks and increasingly rural district populations nationwide each year. Domestic Indian manufacturers increasingly supply serology and rapid test kits that previously relied on imported specifications, giving the country meaningful production self-sufficiency and expanding distribution capability across its diagnostic network. This capacity buildout gives India outsized influence over regional demand growth, since Indian laboratory investment decisions convert directly into testing orders at meaningful, repeatable scale nationwide. Few other national markets currently match this combination of scale and momentum.
Market Impact: Limits genetic testing to 12%

Market Restraints and Challenges

Biopsy Confirmation Requirement Slows Diagnostic Pathways

Most clinical guidelines still require endoscopic biopsy confirmation following a positive serology result before a formal celiac disease diagnosis, a requirement that keeps the overall diagnostic pathway considerably longer than serology testing alone would suggest. The root cause is evidentiary caution: gastroenterology societies have been slow to fully endorse serology-only diagnosis despite growing accuracy data supporting it in select patient populations. The impact falls hardest on patients in regions with limited endoscopy capacity, since biopsy scheduling backlogs can delay confirmed diagnosis by months. Some professional bodies are responding by revising pediatric guidelines to allow biopsy-free diagnosis in defined cases.
Market Impact: Expands screened patient volume by

Limited Reimbursement Constrains Genetic Testing Adoption

Genetic testing for HLA-DQ2 and DQ8 markers carries considerably higher cost than serology screening, and insurance reimbursement policies vary widely across payers, a limitation that leaves genetic testing underused despite its strong negative predictive value in ambiguous diagnostic cases. The root cause is positioning: payers often classify genetic testing as confirmatory rather than essential, reimbursing it inconsistently relative to serology and biopsy. The impact falls hardest on patients with ambiguous serology results, since they cannot always access the genetic test that would resolve their diagnostic uncertainty. Some manufacturers are responding by bundling genetic testing into broader diagnostic panel pricing.
Market Impact: Cuts diagnostic pathway delay by 26
3 additional market trends, 3 additional growth drivers, and 4 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows test type, the single classification logic that determines diagnostic mechanism, turnaround time, and reimbursement pathway. Serology, genetic, biopsy, and point-of-care formats each carry distinct commercial properties, so commercial position tracks test type rather than care setting alone across every manufacturer profiled in this review. That same logic determines pricing power across every manufacturer profiled here.
celiac-disease-diagnostics-market-market-share-analysis-1787305266533

Point-of-Care Rapid Tests

Point-of-care testing grows fastest at 13.2%, roughly 1.57 times the overall market rate, as clinics and pharmacies increasingly adopt CLIA-waived rapid antibody formats that deliver results within twenty minutes rather than requiring a multi-day laboratory referral. This format detects tTG-IgA antibodies directly from a fingerstick blood sample, delivering meaningfully faster diagnostic pathway initiation compared with central laboratory serology alone. Biomerica and Trinity Biotech lead this segment's rapid-format pipeline, while AESKU.GROUP and Orgentec Diagnostika compete on accuracy validation depth and distribution breadth. Growing rural and pharmacy-based screening adoption continues expanding this segment's addressable base considerably beyond its original urgent-care origins across major primary care networks worldwide. Distribution partnerships with pharmacy chains keep strengthening this segment's reach.
CAGR 13.2%

Genetic Testing (HLA-DQ2/DQ8)

Genetic testing grows second-fastest at 10.8%, about 1.29 times the overall rate, as gastroenterologists increasingly order HLA-DQ2 and DQ8 panels to resolve ambiguous serology results or rule out celiac disease in symptomatic patients directly. This format identifies the genetic markers nearly universally present in confirmed celiac disease patients, delivering strong negative predictive value that can eliminate the need for biopsy in select cases. Thermo Fisher Scientific and QIAGEN lead this segment's panel development, while R-Biopharm and Bio-Techne compete on turnaround time and laboratory partnership breadth. Growing use in pediatric and ambiguous-serology cases continues expanding this segment's addressable population beyond its original confirmatory niche. Payer interest in genetic confirmation keeps rising steadily too, especially in pediatric care.
CAGR 10.8%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America leads at 28% of the total, reflecting concentrated primary care screening and reimbursement infrastructure that few other regions currently match. Western Europe and East Asia follow closely behind, each anchored by distinct regional demand drivers, while the remaining four regions complete global distribution.

North America

The United States drives most of North America's 28% share, anchored by widespread primary care serology screening and consistent insurance reimbursement for tTG-IgA panels across major health systems nationwide. Canada's smaller but comparably structured healthcare system adds incremental demand beyond American volume specifically. Academic medical centers across the region continue publishing celiac prevalence and screening yield data that keeps expanding physician awareness among newer practitioners. Growth of 9.2% reflects steady screening expansion more than any single new testing product launch alone. Point-of-care adoption is accelerating fastest in rural and underserved areas lacking convenient laboratory access. Growing pharmacy-based point-of-care adoption is accelerating fastest in rural and underserved areas lacking convenient laboratory access nationwide.
Share: 28% | CAGR: 9.2% (2026 to 2036)

Western Europe

Finland, Italy, and the United Kingdom anchor Western Europe's 24% share, reflecting some of the world's highest diagnosed celiac disease prevalence and long-established national screening awareness campaigns across public health systems. DiaSorin and EUROIMMUN's core European operations serve both domestic clinical networks and export markets across the continent. Germany and France contribute meaningful genetic and serology testing demand beyond the core Nordic and Italian base. Growth of 6.8%, the softest pace among the seven regions tracked, reflects this underlying market maturity rather than weakening underlying diagnostic demand overall across the region's established systems. National screening awareness campaigns keep driving diagnosis rates well above the global average across most participating public health systems.
Share: 24% | CAGR: 6.8% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
celiac-disease-diagnostics-market-country-cagr-analysis-1787305267046

How Diagnostics Makers Can Defend Test Margin

Margin increasingly depends on physician education partnership depth and laboratory integration rather than raw test kit volume alone, as clinics demand documented accuracy evidence alongside dependable turnaround service. The four levers below target service, certification, and financing revenue that celiac diagnostics manufacturers have left underexploited, converting a commodity test kit sale into a longer, more defensible laboratory relationship over time.

Bundle Funded Physician Education Support Programs

Manufacturers increasingly bundle funded physician education partnerships with serology test launches, capturing service revenue that manufacturers without education partnerships leave on the table since smaller primary care practices often lack in-house expertise to interpret ambiguous celiac serology results confidently. This service model captures 8% to 14% incremental revenue beyond commodity test kit pricing, since buyers increasingly value manufacturers who can accelerate accurate diagnosis rather than suppliers who simply ship kits without ongoing clinical support. Building this capability requires investment in education partnership staff, and the margin differential justifies the added cost over a multi-year relationship.
Market Impact: Generates 8% to 14% recurring annua

Offer Extended Result Accuracy Warranty Coverage

Manufacturers increasingly offer extended accuracy warranties that guarantee documented sensitivity and specificity beyond the standard test specification, capturing premium pricing that manufacturers without performance guarantees leave on the table since risk-averse laboratories pay meaningfully more for documented reliability assurance. Buyers pay 7% to 12% more for tests backed by extended accuracy warranties than for equivalent products without guaranteed performance, since warranty-backed protection directly reduces the laboratory's misdiagnosis liability exposure. This reputation compounds into durable advantage over successive product cycles and repeat laboratory contracts. This warranty-backed positioning increasingly appears in formal laboratory procurement evaluation criteria across major markets.
Market Impact: Commands 7% to 12% higher average u

Guarantee Multi-Year Laboratory Supply Agreements Directly

Manufacturers increasingly offer guaranteed multi-year supply agreements to strategic reference laboratory customers, capturing specification loyalty that manufacturers without allocation guarantees leave on the table since laboratories require dependable kit availability for testing volume planning amid genuine manufacturing constraints. Thermo Fisher and DiaSorin both report that supply commitments directly determine which laboratory contracts they can even secure, independent of unit pricing alone. Building this capability requires investment exceeding $2 million per program, but manufacturers who commit early lock in relationships before competitors match the depth offered to strategic accounts. within the first two contract renewal cycles.
Market Impact: Wins laboratory contracts each wort

Expand Regional Manufacturing Near Testing Hubs

Import tariffs and delivery lead time on reagents manufactured outside major testing hubs have risen enough that regional manufacturing capacity, closer to laboratory and clinic procurement clusters, increasingly beats import economics even at somewhat higher local production cost. Manufacturers building manufacturing capacity in India, China, and Mexico, rather than relying entirely on centralized production, cut landed cost by roughly 14% while also shortening lead times that matter increasingly to fast-track testing fulfillment across nearly every regional market segment tracked here. This shift requires upfront capital investment, but manufacturers who move early capture share from import-dependent competitors quickly.
Market Impact: Cuts landed testing costs by roughl

Who Controls the Margin Pool

Five manufacturers control under half of global revenue, a moderately fragmented picture reflecting the relatively low technical barrier to entry in serology reagent manufacturing compared with more complex diagnostic categories. Thermo Fisher and DiaSorin lead on scale, though Thermo Fisher leads laboratory-based serology breadth while DiaSorin leads automated platform integration depth. Revenue, the basis used here, favors manufacturers with the broadest laboratory distribution network.
Competitive activity runs across three dimensions. Manufacturers race to expand point-of-care rapid test portfolios before rivals lock in long-term pharmacy and clinic distribution agreements. Physician education partnerships and turnaround guarantees have become a differentiator, as risk-averse laboratories increasingly prefer manufacturers who can document guaranteed accuracy performance. Indian and Chinese domestic manufacturers are winning standard serology specification deals that once belonged primarily to established Western suppliers.

Pressure is building from two directions that could reshuffle rankings within the decade. Indian and Chinese regional manufacturers, still largely absent from the global key player list, are scaling serology and rapid test production to serve domestic rising screening volume closer to home. Specialized point-of-care and genetic testing makers, outside the established central laboratory serology franchise, are proving that documented rapid-result reliability can command pricing conventional manufacturers struggle to match.
celiac-disease-diagnostics-market-company-positioning-matrix-1787305267570

Competitive Moat and Risk Dimensions

THERMO FISHER SCIENTIFIC INC.

Moat: Broadest Laboratory Distribution Network

Thermo Fisher holds one of the broadest laboratory distribution networks of any diagnostics manufacturer, spanning multiple test formats built on years of accumulated reagent manufacturing and clinical validation data. That breadth lets it bid on multi-site reference laboratory contracts that narrower point-of-care specialists cannot match on documented reliability depth.
THERMO FISHER SCIENTIFIC INC.

Risk: Narrower Point-of-Care Portfolio Presence

Thermo Fisher's core strength in central laboratory serology leaves it less positioned to capture the rapidly growing point-of-care testing segment compared with competitors who built dedicated rapid-format manufacturing capability earlier in the category's development cycle. This gap could limit its addressable volume growth over the coming decade.
DIASORIN S.P.A.

Moat: Deep Automated Platform Integration

DiaSorin holds particularly deep automated testing platform integration expertise, built on years of instrument development investment that positions it closest to high-volume reference laboratory customers seeking workflow efficiency. That specialization converts directly into stronger laboratory relationships and contract renewal rates across major reimbursement markets tracked in this review.
DIASORIN S.P.A.

Risk: Limited Genetic Testing Portfolio Depth

DiaSorin's core strength in automated serology platforms leaves it less positioned to compete in the growing genetic testing segment compared with manufacturers who built dedicated HLA panel development capability earlier. This gap could limit its addressable volume growth over the coming decade of rising demand.

Players Tracked

Prominent Players

Thermo Fisher Scientific Inc.
DiaSorin S.p.A.
Bio-Rad Laboratories, Inc.
Werfen (INOVA Diagnostics)
EUROIMMUN AG

Other Key Players

Eurospital S.p.A.
Biomerica, Inc.
AESKU.GROUP GmbH
Orgentec Diagnostika GmbH
Trinity Biotech plc
R-Biopharm AG
Zeus Scientific, Inc.
Hycor Biomedical LLC
Certest Biotec S.L.
Abbott Laboratories
Siemens Healthineers AG
QIAGEN N.V.
Bio-Techne Corporation
Meridian Bioscience, Inc.
Diagnostica Longwood S.r.l.

Recent Developments

MARCH 2025

Thermo Fisher Expands Serology Reagent Manufacturing In Europe

Thermo Fisher expanded serology reagent production capacity at an existing European facility, aiming to meet growing demand from reference laboratories and hospital networks across the continent. The expansion added meaningful annual capacity without requiring an entirely new greenfield manufacturing site directly, strengthening export-bound reagent supply.
Signal: Signals established manufacturers are prio
JULY 2025

DiaSorin Signs Distribution Agreement With An Indian Laboratory Network

DiaSorin signed a multi-year distribution agreement with a major Indian laboratory network to provide automated serology testing across several diagnostic centers. The agreement was structured as a direct distribution contract, not a joint venture or equity arrangement, ahead of a planned demand ramp across the region.
Signal: Signals established manufacturers are secu
NOVEMBER 2025

Werfen Acquires A Regional Point-of-Care Testing Specialist

Werfen completed the acquisition of a regional point-of-care rapid testing technology specialist, adding decentralized diagnostics capability to its existing laboratory portfolio. The transaction was a full acquisition, not a licensing or minority equity arrangement. The specialist brought rapid-format technology Werfen had previously lacked entirely across its portfolio.
Signal: Signals established manufacturers are cons

What Actually Drives Celiac Test Cost

Antibody reagent and antigen sourcing account for roughly 38% of production cost, sourced from specialty biochemical manufacturing facilities concentrated in the United States, Germany, and increasingly China. Quality assurance and calibration costs add another 24%, while packaging and cold-chain distribution costs make up most of the remainder across manufacturer operations tracked here. Reagent sourcing remains the single largest cost driver by far.
Antibody reagent costs spiked in 2021 and 2022 as broader biochemical manufacturing supply chain disruption raised the cost of specialty inputs shared with other immunoassay diagnostics industries competing for the same processing capacity. Thermo Fisher's 2022 annual report cited elevated reagent manufacturing costs as a direct pressure on diagnostics margins that year, and DiaSorin reported comparable pressure, pushing several manufacturers toward temporary production prioritization until commodity pricing eased into 2023 and 2024.

Smaller regional manufacturers carry the sharpest exposure, since they lack the purchase volume to negotiate long-term reagent supply contracts that Thermo Fisher and DiaSorin secure directly with specialty biochemical producers. Geographic exposure varies too: manufacturers sourcing domestic antibody inputs face lower cost volatility than those dependent on imported specialty reagents, a gap that widens whenever global commodity prices spike against relatively stable domestic pricing structures.
celiac-disease-diagnostics-market-cost-volatility-analysis-1787305267765

Lock Multi-Year Reagent Supply Agreements

Manufacturers with sufficient purchase volume are negotiating multi-year antibody reagent supply agreements directly with biochemical producers, trading pricing flexibility for guaranteed allocation during industry-wide shortages. This approach favors the largest manufacturers, since minimum volume commitments required for favorable terms sit beyond what smaller regional producers can commit to comfortably. Smaller producers lack this negotiating leverage entirely.

Qualify Alternative Reagent Sourcing Networks

Some manufacturers now qualify alternative antibody reagent sourcing networks that reduce single-supplier dependency across multiple product lines rather than relying entirely on one biochemical producer, trading some cost optimization for meaningfully improved supply flexibility. Smaller producers often lag several months behind on this qualification work. Smaller producers, lacking dedicated qualification staff, often lag behind larger competitors on this same work.

Build Regional Manufacturing Capacity Near Demand

Opening manufacturing facilities closer to major Asian diagnostics markets, as several manufacturers have done in India and China, cuts logistics cost and currency exposure even when core reagent inputs still ship from concentrated global suppliers. Manufacturers who delay this investment risk losing regional accounts to nearer competitors. Manufacturers who delay this investment risk losing long-term regional accounts to nearer competitors.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with clear margin separation. Volume-tier products, standard tTG-IgA serology panels sold largely on price into commodity laboratory channels, compete hard and earn modestly. Premium certified products, covering automated multiplex serology platforms meeting documented sensitivity specifications, earn considerably more because instrument integration and validation depth support pricing. Next-generation point-of-care and genetic testing formats occupy the top
The tension here is common to specialty diagnostics businesses: volume serology revenue funds the manufacturing scale premium products depend on, yet volume growth alone cannot fund the platform development next-generation solutions require. Manufacturers leaning too heavily into premium positioning risk losing the manufacturing scale that makes market entry viable in price-sensitive laboratory channels, while volume players cede premium specification entirely to diversified rivals.

High-value pools concentrate where decentralized convenience, diagnostic accuracy, and physician trust intersect: point-of-care and genetic testing products serving clinics willing to pay for verified, documented rapid-result reliability. That intersection is a minority of revenue globally but expanding quickly, which is why the next-generation tier grows fastest even while representing a modest volume share overall.

Volume / Commodity-Adjacent Tier

Standard tTG-IgA serology panels sold largely on price into commodity laboratory channels, competing directly against low-cost regional producers across most price-sensitive markets. Margins here compress steadily each year as generic competition intensifies.
Gross Margin: 18%-26%

Premium / Certified Tier

Automated multiplex serology platforms meeting documented sensitivity specifications, sold to laboratories willing to pay for workflow integration and proven reliability. This tier increasingly anchors long-term reference laboratory relationships and repeat volume.
Gross Margin: 28%-38%

Sustainability / Regulatory / Next-Generation Tier

Point-of-care and genetic testing formats representing the decentralized diagnostics innovation frontier, priced at a substantial premium justified by convenience and expanding clinical application scope. Few manufacturers currently compete here, leaving considerable room for early leadership.
Gross Margin: 35%-48%
celiac-disease-diagnostics-market-portfolio-architecture-1787305268269

How Celiac Testing Demand Actually Commits

Demand here commits through a laboratory qualification and physician ordering-pattern cycle rather than a point-of-sale purchase decision. A reference laboratory that qualifies a specific serology platform for its standard workflow typically commits to that manufacturer for years, since switching platforms requires re-validating assay performance already submitted to accreditation reviewers. That long-commitment structure makes this market behave like a platform-based annuity once a manufacturer
Adoption depth varies by application category. Reference and hospital laboratories adopt automated multiplex platforms readily, given the testing volume that makes workflow integration essential rather than optional. Primary care and rural clinics adopt point-of-care formats more readily too, prioritizing turnaround speed over marginal cost differences between comparable rapid tests. Gastroenterology specialists occupy a distinct position, often prioritizing genetic and biopsy confirmation depth over screening convenience alone.

Younger primary care physicians increasingly research published sensitivity and specificity data directly rather than relying entirely on manufacturer sales representatives that previous practitioner generations depended on for test selection guidance. That shift is pushing manufacturers toward more transparent published clinical data and digital ordering tools, even though long-term laboratory specification relationships remain the actual purchasing mechanism for most reference laboratory accounts today.
celiac-disease-diagnostics-market-end-use-penetration-index-1787305268759

Where This Market Rewards Testing Access

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / POINT-OF-CARE EXPANSION STRATEGY

Winners will build decentralized testing networks first

Raw serology accuracy alone no longer separates leading manufacturers, since most competitors can eventually match a given sensitivity specification within a few product cycles. What actually separates winners is the depth of point-of-care distribution reaching undiagnosed patients outside major laboratory networks, because a technically capable serology test without decentralized reach cannot win the diagnosis-funnel race that increasingly determines long-term physician loyalty. Manufacturers building dedicated rapid-format capability, rather than waiting for organic laboratory referral growth, will out-earn technically comparable rivals over the coming decade.
02 / REGIONAL MANUFACTURING FOOTPRINT

Local production capacity will decide Asian market access

Trade cost and delivery lead time, not raw manufacturing cost alone, increasingly determine which manufacturers can compete profitably as India and China scale their own diagnostics manufacturing base rapidly. Manufacturers who build regional manufacturing capacity early will capture access that purely import-dependent competitors cannot match, regardless of how competitive their underlying test pricing might otherwise be under normal market conditions. Those relying entirely on distant centralized manufacturing will find themselves increasingly unable to serve the fastest-growing Asian markets within this decade.
03 / PHYSICIAN EDUCATION INVESTMENT

Education partnerships will matter more than bulk sales

Manufacturers still competing purely on bulk test kit price are leaving durable revenue on the table that physician education partnerships and interpretation support services already capture successfully for service-forward competitors across major markets. These recurring revenue streams persist independent of the awareness-driven demand swings that otherwise define this market's uneven regional growth pattern tied to screening campaign timing. Companies that build genuine education and support capability early will earn materially more per laboratory relationship over a decade than those still selling only test kits.
04 / GENETIC PANEL INVESTMENT

Genetic testing depth will matter more than legacy volume

Even where established serology demand keeps growing steadily, long-term margin growth is increasingly shaped by how quickly manufacturers secure genetic panel specification across the fastest-growing ambiguous-case testing pathway, a clinical transition individual manufacturers cannot simply accelerate through marketing alone. Manufacturers who invest early in HLA panel research and turnaround engineering will capture positioning ahead of competitors still dependent entirely on legacy serology demand streams. This constraint will matter more to realized long-term margin than any single near-term pricing decision across every category tracked here.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Celiac Disease Diagnostics Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Celiac Disease Diagnostics Exposure Evaluation 2025-26
CLIENT PROFILE
A regional reference laboratory network approached MMA while evaluating whether to expand its point-of-care testing partnerships or continue relying primarily on central laboratory serology processing across its client base. The network reported annual celiac test volume near 84,000 panels, with roughly 71% processed through central laboratory workflows (client-reported, unverified by MMA). The network's leadership sought an outside benchmark before committing further capital.
STRATEGIC CHALLENGE
Leadership believed expanded point-of-care partnerships would meaningfully improve rural client retention, but nobody had modeled the additional distribution investment and physician training timeline against the potential volume advantage, nor assessed which manufacturer would best support the network's existing accreditation status. This uncertainty delayed the expansion decision by several months. No internal owner had been assigned to resolve the decision.
MMA APPROACH
MMA benchmarked point-of-care partnership offerings across four manufacturers against the network's existing accreditation requirements, modeled distribution investment and timeline scenarios against comparable prior rollouts, and interviewed procurement staff at three regional clinic groups on real-world adoption criteria for rapid testing versus central laboratory referral and reviewed comparable published accuracy data.
KEY FINDINGS
  1. A phased point-of-care rollout plan building on the network's existing client relationships offered the clearest path to adoption, based on comparable manufacturer rollout timelines (client-reported, unverified by MMA).
  2. Clinic interviews revealed stronger adoption willingness for rapid testing than the network's own prior market research had indicated. This gap influenced the final rollout decision materially.
  3. The training timeline for point-of-care certified staff ran only modestly longer than the network's standard onboarding cycle, given shared laboratory accreditation infrastructure.
  4. Two of the four manufacturers evaluated had secured meaningfully stronger clinic relationships after launching comparable point-of-care programs than central-laboratory-only comparable peer networks had achieved.
CLIENT PROFILE
A regional reference laboratory network approached MMA while evaluating whether to expand its point-of-care testing partnerships or continue relying primarily on central laboratory serology processing across its client base. The network reported annual celiac test volume near 84,000 panels, with roughly 71% processed through central laboratory workflows (client-reported, unverified by MMA). The network's leadership sought an outside benchmark before committing further capital.
STRATEGIC CHALLENGE
Leadership believed expanded point-of-care partnerships would meaningfully improve rural client retention, but nobody had modeled the additional distribution investment and physician training timeline against the potential volume advantage, nor assessed which manufacturer would best support the network's existing accreditation status. This uncertainty delayed the expansion decision by several months. No internal owner had been assigned to resolve the decision.
MMA APPROACH
MMA benchmarked point-of-care partnership offerings across four manufacturers against the network's existing accreditation requirements, modeled distribution investment and timeline scenarios against comparable prior rollouts, and interviewed procurement staff at three regional clinic groups on real-world adoption criteria for rapid testing versus central laboratory referral and reviewed comparable published accuracy data.
KEY FINDINGS
  1. A phased point-of-care rollout plan building on the network's existing client relationships offered the clearest path to adoption, based on comparable manufacturer rollout timelines (client-reported, unverified by MMA).
  2. Clinic interviews revealed stronger adoption willingness for rapid testing than the network's own prior market research had indicated. This gap influenced the final rollout decision materially.
  3. The training timeline for point-of-care certified staff ran only modestly longer than the network's standard onboarding cycle, given shared laboratory accreditation infrastructure.
  4. Two of the four manufacturers evaluated had secured meaningfully stronger clinic relationships after launching comparable point-of-care programs than central-laboratory-only comparable peer networks had achieved.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 5 months): Finalize the phased point-of-care rollout plan and begin clinic partner outreach directly. with regional decision-makers directly. Phase 2: Phase 2 (5 to 12 months): Complete initial deployment while maintaining existing central laboratory referral relationships intact. across all participating client sites. Phase 3: Phase 3 (12 to 20 months): Launch full point-of-care availability to eligible clinics, monitoring early adoption and accuracy results closely.
OUTCOME
The network proceeded with the phased point-of-care rollout plan and began clinic outreach on schedule, tracking meaningfully faster than the originally projected timeline, with initial deployment completed ahead of the internal target date. The network reported strong early client retention improvement ahead of the anticipated rollout expansion (client-reported, unverified by MMA).

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Celiac Disease Diagnostics Market?

The market stood at USD 0.9 billion in 2025, based on MMA Primary Research Dataset findings. Rising physician awareness remains the largest driver of overall screening demand.

How large will the Celiac Disease Diagnostics Market be by 2036?

MMA projects the market will reach USD 2.19 billion by 2036 under the base case scenario, representing roughly 2.24 times the 2026 opening value across the eleven-year forecast period.

What is the CAGR for the Celiac Disease Diagnostics Market 2026 to 2036?

The base case CAGR is 8.4% annually. MMA's bull scenario reaches 9.7% while the bear scenario, reflecting reimbursement and access constraints, runs closer to 7.1% over the forecast period.

Which segment is growing fastest?

Point-of-care rapid tests lead at 13.2% CAGR, roughly 1.57 times the overall market rate, as CLIA-waived formats steadily replace multi-day laboratory referral pathways across primary care networks.

Who are the major companies in the Celiac Disease Diagnostics Market?

Thermo Fisher Scientific, DiaSorin, Bio-Rad Laboratories, Werfen, and EUROIMMUN lead the market, together controlling an estimated 48% of global revenue on a consistent basis measured across every test category.

Which country is growing fastest?

India posts the fastest national growth at 10.6% CAGR, driven by its rapidly expanding diagnostic laboratory network and rising physician awareness. Domestic manufacturers increasingly compete for regional export orders.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Test Type

  • Serology Testing (tTG-IgA, EMA, DGP)
  • Genetic Testing (HLA-DQ2/DQ8)
  • Endoscopy And Biopsy Confirmation
  • Point-of-Care Rapid Tests

By End-Use Setting

  • Hospital And Reference Laboratories
  • Primary Care Clinics
  • Retail Pharmacies
  • Ambulatory Diagnostic Centers

By Commercial Dimension

  • Direct Laboratory Sales
  • Distributor And Wholesaler Channels
  • Payer And Insurance Partnerships
  • Physician Education Partnerships

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The celiac disease diagnostics market covers serology, genetic, endoscopic biopsy, and point-of-care testing products and services used specifically to diagnose celiac disease. It excludes general gastrointestinal diagnostic panels and celiac disease treatments such as gluten-free dietary products or investigational therapeutics.
Quantitative Units
USD billions (current prices); test panels and units shipped where applicable
Segmentation Dimensions
By Test Type; By End-Use Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Canada, China, Japan, South Korea, India, Australia, Vietnam, Indonesia, Finland, Italy, UK, Germany, France, Spain, Brazil, Mexico, UAE, Saudi Arabia, South Africa, Poland, Czech Republic, Hungary, Romania, Russia, and additional markets relevant to this sector
Key Companies Profiled
Thermo Fisher Scientific Inc., DiaSorin S.p.A., Bio-Rad Laboratories, Inc., Werfen (INOVA Diagnostics), EUROIMMUN AG, Eurospital S.p.A., Biomerica, Inc., AESKU.GROUP GmbH, Orgentec Diagnostika GmbH, Trinity Biotech plc, R-Biopharm AG, Zeus Scientific, Inc., Hycor Biomedical LLC, Certest Biotec S.L., Abbott Laboratories, Siemens Healthineers AG, QIAGEN N.V., Bio-Techne Corporation, Meridian Bioscience, Inc., Diagnostica Longwood S.r.l.
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-250
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Celiac Disease Diagnostics Market Report (2026 to 2036).

The full MMA Celiac Disease Diagnostics report sizes the market across four test-type categories, four end-use settings, four commercial channels, and seven regions through 2036. It profiles 20 participants on a consistent revenue basis, scoring the top five on assay accuracy validation, laboratory distribution breadth, and physician education partnership reliability. Scenario models quantify how point-of-care adoption, genetic panel uptake, and India's laboratory infrastructure expansion move both demand and realizable pricing. The report also includes delivered-cost modelling by test type, a regional reimbursement policy tracker, and a competitive benchmarking tool built for manufacturer strategy, laboratory procurement, and investor due diligence teams.
Four-category test-type segmentation with regional cross-tabulation
Reimbursement policy tracker across twelve major markets
Competitive benchmarking on consistent revenue basis
Delivered-cost modelling by test type and region
Scenario models for point-of-care and genetic testing demand
India diagnostic laboratory infrastructure analysis by manufacturer

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts